ClinicalTrials.gg

Program

olomorasib

Also written as “Olomorasib”, “LY3537982” and “[¹⁴C]-LY3537982”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Renal Insufficiency · Hepatic Insufficiency, led by 3 companies.

Furthest: phase 3, since Nov 1, 202316 company-led studies, 7 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly145 open or runningphase 3since Nov 1, 2023Jul 2, 2021Apr 2027phase 2 · NCT04956640
Daiichi Sankyo11 open or runningphase 2since Oct 16, 2026Oct 16, 2026Sep 30, 2029phase 2 · NCT07890714
Johnson & Johnson11 open or runningphase 2since Nov 10, 2025Nov 10, 2025Nov 30, 2028phase 2 · NCT07227025
  • Named in Eli Lilly’s own pipeline as Olomorasib, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: AstraZeneca and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Jul 2, 2021.

  1. Apr 11, 2023Phase 1 study in HealthyEli Lilly · NCT05824858 · 48 enrolled · United States
  2. Jun 4, 2023Phase 1 study in HealthyEli Lilly · NCT05901311 · 16 enrolled · United States
  3. Oct 27, 2023Phase 1 study in HealthyEli Lilly · NCT06111521 · 35 enrolled · United States
  4. Nov 1, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT06119581 · 1,264 planned · United States, Australia, Austria and more
  5. Jan 24, 2024Phase 1 study in Advanced Solid TumorsEli Lilly · NCT06235983 · 12 enrolled · China
  6. Dec 2, 2024Phase 1 study in Hepatic InsufficiencyEli Lilly · NCT06719128 · 46 enrolled · United States
  7. Mar 18, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT06890598 · 700 planned · United States, Australia, Austria and more
  8. Jun 26, 2025Phase 1 study in HealthyEli Lilly · NCT07044271 · 120 enrolled · United States
  9. Aug 13, 20252 phase 1 studiesEli Lilly · NCT07124013, NCT07137689
  10. Nov 10, 2025Johnson & Johnson's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Johnson & JohnsonJohnson & Johnson · NCT07227025 · 60 planned · United States, Canada, China and more
  11. Feb 24, 2026Phase 1 study in HealthyEli Lilly · NCT07439250 · 15 enrolled · United States
  12. Aug 26, 2026Phase 1 study in Healthy VolunteersEli Lilly · NCT07794592 · 24 planned · United States
  13. Sep 4, 2026Phase 2 study in Colorectal NeoplasmsEli Lilly · NCT07814417 · 50 planned · United States, China, Spain
  14. Oct 16, 2026Daiichi Sankyo's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Daiichi SankyoDaiichi Sankyo · NCT07890714 · 268 planned · Taiwan

Ahead

  1. Apr 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT04956640
  2. Nov 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT06119581
  3. Nov 2028Primary completion: phase 2 study in Colorectal NeoplasmsEli Lilly · NCT07814417
  4. Nov 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT07227025

TargetBeta

“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, olomorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, …”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07890714Carcinoma, Non-Small-Cell Lung · Taiwan2RecruitingDaiichi SankyoSep 30, 2029268
NCT07814417Colorectal Neoplasms · United States, China, Spain2Not yet recruitingEli LillyNov 202850
NCT07794592Healthy Volunteers · United States1RecruitingEli LillyOct 202624
NCT07439250Healthy · United States1CompletedEli LillyApr 17, 202615
NCT07227025Carcinoma, Non-Small-Cell Lung · United States, Canada, China and more2RecruitingJohnson & JohnsonNov 30, 202860
NCT07137689Renal Insufficiency · United States1CompletedEli LillyApr 10, 202632
NCT07124013Healthy · Japan1CompletedEli LillyJan 5, 2026191
NCT07044271Healthy · United States1CompletedEli LillyNov 8, 2025120
NCT06890598Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingEli LillyMay 2029700
NCT06719128Hepatic Insufficiency · United States1CompletedEli LillyAug 25, 202546
NCT06235983Advanced Solid Tumors · China1CompletedEli LillyJul 2, 202512
NCT06119581Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3RecruitingEli LillyNov 20271,264
NCT06111521Healthy · United States1CompletedEli LillyApr 1, 202435
NCT05901311Healthy · United States1CompletedEli LillyAug 10, 202316
NCT05824858Healthy · United States1CompletedEli LillyJun 17, 202348
NCT04956640Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2Active, not recruitingEli LillyApr 2027540

How it is read

Names in the registry

  • “Olomorasib”, 8 entries
  • “LY3537982”, 7 entries
  • “[¹⁴C]-LY3537982”, 2 entries
  • “Olomorasib test”, 1 entry
  • “Olomorasib reference”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.